Background
Hepatocellular carcinoma (HCC) remains a major global health burden with limited effective therapeutic strategies. Although chimeric antigen receptor (CAR) T-cell therapy has shown encouraging potential, its efficacy in HCC is profoundly co…
Science Immunology, Volume 11, Issue 121, July 2026.
Science Immunology, Volume 11, Issue 121, July 2026.
Curr Opin Immunol. 2026 Jul 30;102:102814. doi: 10.1016/j.coi.2026.102814. Online ahead of print. ABSTRACT Spatial transcriptomic and proteomic atlases have enabled mapping of gene programs within intact tissues, but these measurements remain largely descriptive and do not define the mechanisms controlling tissue biology. Pooled CRISPR screening provides scalable causal interrogation of gene function but remains largely … Read more
Trends Immunol. 2026 Jul 30:S1471-4906(26)00182-1. doi: 10.1016/j.it.2026.07.003. Online ahead of print. ABSTRACT Homing pigeons’ navigation in darkness relies on Earth’s magnetic field. However, the underlying mechanism of magnetoreception remains poorly understood. Recently, Lisowski et al. demonstrated that superparamagnetic hepatic macrophages are potential magnetoreceptors that detect and transmit geomagnetic information to support the navigation of pigeons. … Read more
BackgroundAcute leukemia (AL) is a malignant hematological disorder, with two main subtypes: acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The incidence rate of AML and ALL is estimated at approximately 2.7 and 1.5 per 100,000 pe…
BackgroundResponse to secukinumab in psoriasis varies over time and is not fully captured by single timepoint endpoints. Baseline features associated with long-term response trajectories remain unclear.ObjectiveTo identify 52-week secukinumab response …
BackgroundMixed-type IgA vasculitis (IgAV) is common in clinical practice, but its internal heterogeneity and prognostic significance, especially in renal involvement, remain unclear. This study aimed to characterize mixed-type IgAV, compare renal risk…
BackgroundAdjuvant treatment of melanoma patients with PD-1-based immunotherapy has improved recurrence rate, and became a standard treatment. However, a considerable proportion of patients recur within 1–2 years, necessitating the identification of pr…
